Tower Research Capital LLC (Trc) Ascendis Pharma A/S Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 340 shares of ASND stock, worth $41,697. This represents 0.0% of its overall portfolio holdings.

Number of Shares

340

Previous 6,488 94.76%

Holding current value

$41,697

Previous $884,000 94.34%

% of portfolio

0.0%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $694,724 - $943,287	-6,148 Reduced 94.76%	340 $50,000
Q2 2024 Aug 13, 2024	BUY	$121.07 - $153.67 $723,393 - $918,178	5,975 Added 1164.72%	6,488 $884,000
Q1 2024 May 15, 2024	SELL	$123.45 - $159.4 $642,680 - $829,836	-5,206 Reduced 91.03%	513 $77,000
Q4 2023 Feb 13, 2024	BUY	$86.1 - $127.36 $464,165 - $686,597	5,391 Added 1643.6%	5,719 $720,000
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $211,838 - $254,622	-2,449 Reduced 88.19%	328 $30,000
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $74,017 - $103,514	1,058 Added 61.55%	2,777 $247,000
Q1 2023 May 09, 2023	SELL	$104.9 - $126.78 $30,001 - $36,259	-286 Reduced 14.26%	1,719 $184,000
Q4 2022 Feb 10, 2023	BUY	$99.42 - $131.97 $97,630 - $129,594	982 Added 95.99%	2,005 $245,000
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $258,056 - $338,516	-3,071 Reduced 75.01%	1,023 $106,000
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $120,945 - $182,177	1,549 Added 60.86%	4,094 $381,000
Q1 2022 May 12, 2022	SELL	$102.18 - $135.75 $79,700 - $105,885	-780 Reduced 23.46%	2,545 $299,000
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $331,603 - $442,642	2,609 Added 364.39%	3,325 $448,000
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $235,367 - $369,585	-2,089 Reduced 74.47%	716 $114,000
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $317,063 - $378,771	2,607 Added 1316.67%	2,805 $369,000
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $37,476 - $51,999	-300 Reduced 60.24%	198 $26,000
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $40,219 - $48,614	266 Added 114.66%	498 $83,000
Q3 2020 Nov 16, 2020	SELL	$134.29 - $154.32 $484,249 - $556,477	-3,606 Reduced 93.96%	232 $36,000
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $374,629 - $527,157	3,379 Added 736.17%	3,838 $567,000
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $44,527 - $66,605	459 New	459 $52,000
Q3 2019 Nov 05, 2019	SELL	$95.8 - $118.9 $87,752 - $108,912	-916 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$107.11 - $132.09 $59,981 - $73,970	-560 Reduced 37.94%	916 $106,000
Q1 2019 May 14, 2019	BUY	$62.15 - $129.99 $91,733 - $191,865	1,476 New	1,476 $173,000
Q3 2018 Nov 13, 2018	SELL	$63.77 - $76.28 $7,333 - $8,772	-115 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$58.55 - $73.92 $5,972 - $7,539	102 Added 784.62%	115 $8,000
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $506 - $884	13 New	13 $1,000
Q4 2017 Feb 09, 2018	SELL	$31.98 - $40.38 $1,822 - $2,301	-57 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $1,532 - $2,114	57	57 $2,000

Others Institutions Holding ASND

# of Institutions

243

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $6.84B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Ascendis Pharma A/S Transaction History